中华肝脏病杂志最新文献_第7页

[A case of chronic hepatitis B with low-level viremia treated with tenofovir amibufenamide].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240830-00420

C J Cui, J Cui, S X Zang, N Fu

引用次数: 0

[Chronic hepatitis B clinically attains cure by applying a timely adjustment to a medication regimen's twists and turns: a case report].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240826-00395

Q Y Ding, Z K He

引用次数: 0

[Real-world study of tenofovir amibufenamide in the treatment of patients with hepatitis B cirrhosis].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240905-00478

Y Han, A J Zeng, X Y Liang, Y N Liu, K K Jin, H G Ding

{"title":"[Real-world study of tenofovir amibufenamide in the treatment of patients with hepatitis B cirrhosis].","authors":"Y Han, A J Zeng, X Y Liang, Y N Liu, K K Jin, H G Ding","doi":"10.3760/cma.j.cn501113-20240905-00478","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240905-00478","url":null,"abstract":"Objective: To evaluate the short-term antiviral efficacy and safety profile of tenofovir amibufenamide (TMF) in patients with hepatitis B cirrhosis. Methods: The biochemical indexes, renal function, and complication status in patients with hepatitis B cirrhosis who were treated with tenofovir amibufenamide (TMF) in Beijing You'an Hospital Affiliated to Capital Medical University from March 2022 to June 2024 were retrospectively analyzed. Results: A total of 98 cases with hepatitis B cirrhosis were included. Among them, 62 and 36 cases with hepatitis B cirrhosis had previously undergone partial resection for hepatocellular carcinoma. 66.7% (62/93) of the treated patients were HBV DNA negative before treatment. The longest follow-up time for medication was 24 months, with an average follow-up of (14.1±4.7) months. There were no statistically significant differences in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBil) levels at 18 months of treatment compared with those before treatment (P>0.05). The ALT return to normal rate was 91.3%. The HBV DNA negativity rate was 90.6% and 93.5% at 18 and 12 months of follow-up, respectively. There were no significant changes in the estimated glomerular filtration rate (eGFR) and low-density lipoprotein cholesterol (LDL-C) compared with those before treatment (P>0.05). 36 cases were still HBV DNA positive (including 31 treated and 5 never treated) before treatment. A total of 29 cases were followed up for 12 months, and 24 cases (82.8%) had HBV DNA negative conversion. Conclusion: TMF antiviral therapies have an HBV DNA negative rate of over 80% at 12 months and can improve the liver function in patients with hepatitis B cirrhosis. However, there were no significant changes in renal function and blood lipids before and after treatment.","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"30-34"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Successful treatment of a hepatitis B-related acute-on-chronic liver failure patient with adefovir dipivoxil combined with artificial liver and human umbilical mesenchymal stem cells].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240831-00458

J J Niu, F Wang, Y N Xin, L Z Chen

引用次数: 0

[A case of chronic hepatitis B with low-level viremia treated with sequential treatment of tenofovir amibufenamide].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240905-00480

Q Liang

引用次数: 0

[Real-world data of tenofovir amibufenamide therapy for treatment-naïve patients with chronic hepatitis B].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240831-00453

J R Zheng, B Feng, Y D Xie

引用次数: 0

[Clinical efficacy of switching to tenofovir amibufenamide tablets with poor response to entecavir in patients with chronic hepatitis B].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240831-00457

Y Li, W Y Wang

{"title":"[Clinical efficacy of switching to tenofovir amibufenamide tablets with poor response to entecavir in patients with chronic hepatitis B].","authors":"Y Li, W Y Wang","doi":"10.3760/cma.j.cn501113-20240831-00457","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240831-00457","url":null,"abstract":"Objective: To analyze the clinical efficacy of switching to tenofovir amibufenamide tablets with poor response to entecavir in patients with chronic hepatitis B. Method: Forty patients with chronic hepatitis B who had poor responses to entecavir, admitted to Linyi Central Hospital from July 2021 to July 2024, were selected as the study subjects. Among them, 18 and 22 cases were hepatitis B e antigen (HBeAg) negative and positive, respectively. All patients were treated using tenofovir amibufenamide tablets. The differences in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to treatment, at 12 and 24 weeks of treatment, were compared between HBeAg-negative and positive patients.The hepatitis B virus (HBV) DNA negative conversion rate was compared after 12 and 24 weeks of treatment between HBeAg-negative and positive patients. Statistical analysis was performed using t-test, one-way ANOVA, LSD-t test, and χ2 test according to different data. Result: ALT and AST levels were higher in HBeAg-positive than those of HBeAg-negative patients (P＜0.05) prior to treatment. ALT and AST levels were lower in HBeAg-negative and HBeAg-positive patients compared to pre-treatment, while those of HBeAg-negative patients were lower than those of HBeAg-positive patients (P＜0.05) after 12 and 24 weeks of treatment. The HBV DNA negative conversion rate was lower in HBeAg-positive patients than that of HBeAg-negative patients (P＜0.05) after 12 weeks of treatment. There was no statistically significant difference in the HBV DNA conversion rate between HBeAg-positive and HBeAg-negative patients after 24 weeks of treatment (P>0.05). Conclusion: Switching to tenofovir amibufenamide tablets can improve liver function and promote HBV DNA negative conversion with poor response to entecavir in patients with chronic hepatitis B, with better therapeutic effect in HBeAg-negative patients.","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"6-9"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Tenofovir amibufenamide inhibiting low-level viremia and delaying the progression of liver cirrhosis: a case report].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240829-00404

C Y Zhao, C F Nie, Z H Zhao

引用次数: 0

[Two cases of patients with hepatitis B e antigen-positive chronic hepatitis B initially treated with tenofovir amibufenamide].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240930-00522

J H Xin, J J Fan, Y Chen

引用次数: 0

[Evaluation of the efficacy and safety profile of tenofovir amibufenamide at 48 weeks during the treatment of hepatitis B virus-related cirrhosis].

中华肝脏病杂志 Pub Date : 2024-11-30 DOI: 10.3760/cma.j.cn501113-20240904-00475

K Y Hao, X Jiang, Y Dong, H N Sun, Y C Yu

{"title":"[Evaluation of the efficacy and safety profile of tenofovir amibufenamide at 48 weeks during the treatment of hepatitis B virus-related cirrhosis].","authors":"K Y Hao, X Jiang, Y Dong, H N Sun, Y C Yu","doi":"10.3760/cma.j.cn501113-20240904-00475","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240904-00475","url":null,"abstract":"Objective: To evaluate the efficacy and safety profile of tenofovir amibufenamide (TMF) at 48 weeks in patients with hepatitis B virus-related compensated and decompensated stage cirrhosis. Methods: Patients with treatment-naïve or treatment-experienced hepatitis B virus-related cirrhosis with nucleos(t)ide analogues (NA) who met the inclusion and exclusion criteria from 2022 to 2024 were retrospectively collected and divided into the tenofovir amibufenamide group (TMF, n=25) and the tenofovir alafenamide fumarate group (TAF, n=14). The conditional changes in hepatitis B virus DNA (HBV DNA), hepatitis B surface antigen (HBsAg), liver function indexes, serum creatinine (Cr), estimated glomerular filtration rate (eGFR), serum phosphorus, blood lipid profiles, and other variables were compared between and within the groups at baseline and 48 weeks. The t-test or Kruskal-Wallis H test was used to compare the measurement data among the groups. The χ2 test was used for the enumeration data. Results: There were no statistically significant differences in baseline, age, gender, proportion of compensated/decompensated stage cirrhosis, proportion of NA-naive/treatment experienced, liver function indexes, serum Cr, and eGFR between the two groups (P>0.05). There was no statistically significant difference in the proportion of patients with HBV DNA<30 IU/ml (P=1.00) between the two groups, regardless of whether they were NA-naive (P=0.52) or treatment experienced (P=1.00) at 48 weeks. There was no statistically significant difference in HBsAg levels between the TMF and TAF groups (P=0.18) at 48 weeks. There was no statistically significant difference in the decline of HBsAg within each group (P>0.05). The levels of alanine aminotransferase (P<0.001) and aspartate aminotransferase (P=0.045) were significantly lower at 48 weeks than those at baseline, while the albumin level was higher than that at baseline (P=0.004) among the TMF group. There were no statistically significant differences in the rest of the liver function indicators among the TMF and the TAF groups between baseline and 48 weeks (P>0.05). There were no statistically significant differences in Cr (P=0.34) and eGFR levels (P=0.60) at 48 weeks between the TMF and TAF groups.There were no statistically significant differences in Cr (P=0.89) and eGFR levels (P=0.57) at 48 weeks in patients aged<40 years (n=8) compared with baseline in the TMF group. There were no statistically significant differences (P=0.09, P=0.13) in patients with similar aged≥40 years (n=17). The reduction in Cr level (P<0.001) and the increase in eGFR (P<0.001) at 48 weeks were statistically significant in patients aged<40 years (n=3) among the TAF group. There were no statistically significant differences in Cr","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"19-29"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0